SEZ6L2 and neoplasm: Our results indicated that the knockdown of SEZ6L2 efficiently inhibited the volume of HCT116 tumours by 52.3% (shSEZ6L2‐1) and 60.1% (shSEZ6L2‐2) (Figure 5A,B, tumour volume: shNC group, 1138.6 ± 187.3 mm3 vs shSEZ6L2‐1 group, 543.2 ± 113.8 mm3 vs shSEZ6L2‐2 group, 453.8 ± 79.3 mm3).